

Form PTO-1449 (Substitute) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	10/585,017
	Filing Date	June 28, 2006
	First Named Inventor	Jacob Bar-Tana
	Art Unit	1612
	Examiner Name	M. Sznaidman
	Attorney Docket No.	2224/76581/JPW /ACK

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume/issue number(s), publisher, city and/or country where published.	T ²
	1	October 4, 2010 Supplementary European Search Report issued in connection with European Application No. EP 04 80 6716	
	4	PCT International Application Publication No. WO 99/00116 A2, published January 7, 1999 (Bar-Tana)	
	5	Russell et al., "Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β , β' -tetramethylhexadecanedioic acid (MEDICA 16), Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15., no. 7, 1995	
	6	McCarty, M.F., "Peroxisome proliferators as adjuvants for the reverse-electron-transport therapy of obesity: An explanation for the large increase in metabolic rate of MEDICA 16-treated rats," <i>Medical Hypotheses</i> , vol. 53, no. 4, 1999	

EXAMINER SIGNATURE	/Marcos Sznaidman/	DATE CONSIDERED	10/24/2011
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a checkmark here if English language Translation is attached.